NCT07528352 2026-04-14
REBEL
University of Utah
Phase 1 Not yet recruiting
Clinical Trials
185 trialsNCT04488354 2026-04-08
Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T
Calibr, a division of Scripps Research
Phase 1 Completed
NCT06208735 2026-04-03
CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies
British Columbia Cancer Agency
Phase 1 Recruiting
NCT05618366 2026-04-02
Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma
Weill Medical College of Cornell University
Phase 1 Terminated
NCT02051257 2026-03-31
Memory Enriched T Cells Following Stem Cell Transplant in Treating Patients With Recurrent B-Cell Non-Hodgkin Lymphoma
City of Hope Medical Center
Phase 1 Active not recruiting
NCT01479842 2026-03-23
Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma
Ohio State University Comprehensive Cancer Center
Phase 1 Active not recruiting
NCT05359211 2026-03-20
NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma
Fred Hutchinson Cancer Center
Phase 1 Active not recruiting
NCT07478848 2026-03-18
Radiation, Oral Vancomycin, and CAR-T for B-Cell Lymphomas
Abramson Cancer Center at Penn Medicine
Phase 1 Not yet recruiting
NCT06026319 2026-03-16
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
Massachusetts General Hospital
Phase 1 Recruiting
NCT05887167 2026-03-04
Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies
Cedars-Sinai Medical Center
Phase 1 Recruiting
NCT04231877 2026-03-03
Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma
University of Washington
Phase 1 Recruiting
NCT05432635 2026-02-23
Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma
City of Hope Medical Center
Phase 1 Recruiting
NCT05990465 2026-02-23
LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies
Medical College of Wisconsin
Phase 1 Recruiting
NCT06227026 2026-02-17
PRODIGY
University of Utah
Phase 1 Recruiting
NCT06191887 2026-02-13
B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies
Mayo Clinic
Phase 1 Recruiting
NCT04067414 2026-02-11
Exploratory Study of CD19-targeted Chimeric Antigen Receptor T Cells(BZ019) for Relapsed and Refractory B-cell Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Phase 1 Completed
NCT04316624 2026-02-11
A Study of C-CAR066 in Subjects With r/r Diffuse Large B Cell Lymphoma Who Received CD19 CAR-T Therapy
Institute of Hematology & Blood Diseases Hospital, China
Phase 1 Completed
NCT04850495 2026-02-06
Zanubrutinib in Combination With R-PolaCHP (ZaR-PolaCHP) for Newly Diagnosed Diffuse Large B-Cell Lymphoma
Ohio State University Comprehensive Cancer Center
Phase 1 Suspended
NCT05694364 2026-02-06
Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT04323956 2026-02-02
Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma
Mayo Clinic
Phase 1 Active not recruiting
NCT01959698 2026-01-28
Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Stage I-IV Diffuse Large B-cell Lymphoma
Roswell Park Cancer Institute
Phase 1 Active not recruiting
NCT04545762 2026-01-14
Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
University of California, San Francisco
Phase 1 Recruiting
NCT03884998 2025-12-30
Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma
City of Hope Medical Center
Phase 1 Active not recruiting
NCT03479268 2025-11-26
Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma
City of Hope Medical Center
Phase 1 Active not recruiting
NCT03259503 2025-11-10
Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant
M.D. Anderson Cancer Center
Phase 1 Completed
NCT07225439 2025-11-06
Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
Case Comprehensive Cancer Center
Phase 1 Not yet recruiting
NCT01815749 2025-10-06
Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma
City of Hope Medical Center
Phase 1 Active not recruiting
NCT02153580 2025-10-06
Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia
City of Hope Medical Center
Phase 1 Active not recruiting
NCT07168486 2025-09-11
CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas
University of Maryland, Baltimore
Phase 1 Enrolling by invitation
NCT02992522 2025-09-09
Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Ohio State University Comprehensive Cancer Center
Phase 1 Active not recruiting
NCT04007029 2025-09-05
Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia
Jonsson Comprehensive Cancer Center
Phase 1 Active not recruiting
NCT03150329 2025-09-03
Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL.
City of Hope Medical Center
Phase 1 Active not recruiting
NCT04464200 2025-08-24
19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers
Memorial Sloan Kettering Cancer Center
Phase 1 Active not recruiting
NCT05836896 2025-08-24
CARLOTTA01
Technische Universität Dresden
Phase 1 Recruiting
NCT05934838 2025-08-15
A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas
Weill Medical College of Cornell University
Phase 1 Recruiting
NCT06827782 2025-08-15
Cord Blood-derived CAR-NK Cells Targeting CD19 for Refractory/Relapsed Central Nervous System Lymphoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 1 Enrolling by invitation
NCT06859008 2025-08-05
Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
City of Hope Medical Center
Phase 1 Recruiting
NCT06977711 2025-08-05
Loncastuximab and Roflumilast Added to R-CHOP (Lo-(Rituximab and Roflumilast) RR-CHOP) for Naïve High-Risk Diffuse Large B-cell Lymphoma (DLBCL)
The University of Texas Health Science Center at San Antonio
Phase 1 Recruiting
NCT06343376 2025-08-03
Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies
Roswell Park Cancer Institute
Phase 1 Terminated
NCT03843294 2025-07-03
Tumor Associated Antigen Specific T Cells (TAA-T) With PD1 Inhibitor for Lymphoma
Children's National Research Institute
Phase 1 Active not recruiting
NCT03742258 2025-06-18
Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma
Northwestern University
Phase 1 Completed
NCT07024147 2025-06-17
JWCAR239 in Patients With B Cell Non-Hodgkin Lymphoma
Peking University Cancer Hospital & Institute
Phase 1 Not yet recruiting
NCT02303392 2025-06-10
Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT06290622 2025-05-06
PD-1, LAG-3 and TIM-3 Checkpoint Blockade in DLBCL
University of Alabama at Birmingham
Phase 1 Withdrawn
NCT00641381 2025-05-01
Carmustine, Etoposide, Cyclophosphamide, and Stem Cell Transplant in Treating Patients With HIV-Associated Lymphoma
City of Hope Medical Center
Phase 1 Active not recruiting
NCT03939182 2025-04-25
Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT05412290 2025-04-24
Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma
Washington University School of Medicine
Phase 1 Recruiting
NCT03440567 2025-03-26
Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma
City of Hope Medical Center
Phase 1 Completed
NCT01497184 2025-03-13
Infusion of Allogeneic CD19-Specific T Cells From Peripheral Blood
M.D. Anderson Cancer Center
Phase 1 Completed
NCT06464861 2025-02-07
CD19-CARNK/T
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 1 Recruiting